Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TyRx Pharma has raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures.
Subscribe to our email newsletter
In connection with the financing, Jeffrey Leiden, managing director, and Scott Requadt, principal, both of Clarus Ventures, and Arthur Pappas, managing partner, Pappas Ventures, will join TyRx’s board of directors.
William Edelman, CEO of TyRx, said: “The funds from the current financing round will enable our continuing transition from the development stage to commercialization, targeting the market in medical device infection control estimated at $3 billion in the US.”